Salute e Benessere

Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following…

Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that Chief Executive Officer Greg Siokas has further increased his ownership in the Company through continued share acquisitions during November 2025.Specifically, between 19 November and 28 November 2025, Mr. Siokas executed five transactions, acquiring 301,101 shares.So far in 2025, he has added 3,398,055 shares to his holdings...
Nasdaq GlobeNewswire
02/12/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 48 - 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from November 24th to November 28th 2025 Name of the issueIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1124/11/2025FR0010259150300...
Nasdaq GlobeNewswire
02/12/2025

GUERBET : Adjustment of 2025 financial targets.

Adjustment of 2025 financial targetsVillepinte, 2 December 2025, 5.45 p.m.:Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing a downward revision to its financial targets for full-year 2025.Following an inspection by the U.S. Food and Drug Administration (FDA) during the first half of the year, the Guerbet Group developed and initiated the implementation of a compliance plan at its Raleigh site in the United States...
Nasdaq GlobeNewswire
02/12/2025

Surgical Gowns and Drapes Market worth $6.01 billion by 2030 |…

Surgical Gowns and Drapes Market Size & Forecast: Surgical Gowns and Drapes Market Size & Forecast: Surgical Gowns and Drapes Trends & Insights: Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=210282118 The surgical gowns and drapes market is experiencing significant growth driven by several key factors. The increasing prevalence of healthcare-associated infections (HAIs) and the rising number of surgeries highlight the critical need for...
PR Newswire
02/12/2025

BetaGlue Therapeutics Expands its Clinical Trial in Italy after obtaining from…

®Therapeutics (“BetaGlue” or the “Company”) a pioneering Italian clinical-stage oncology company developing an innovative radiotherapy solution for the targeted treatment of solid tumours, is proud to announce that the Italian Ministry of Health (MOH) has approved its Clinical Trial Application for YntraDose ®in the treatment of unresectable Locally Advanced Pancreatic Ductal Adenocarcinoma (LA-PDAC). This authorization follows the recent Clinical Trial Approval from the UK’s Medicines...
Nasdaq GlobeNewswire
02/12/2025

Vaderis Therapeutics Announces The New England Journal of Medicine Publishes…

"These early data suggest that engasertib's targeted AKT inhibition has the potential to deliver clinically meaningful improvements in bleeding for patients with HHT. These findings provide encouraging signs that we may be on a promising path toward a much-needed treatment option for this community, which remains without approved therapies," said Hanny Al-Samkari, MD, The Peggy S. Blitz Endowed Chair in Hematology/Oncology at the Mass General Brigham Cancer Institute, Associate…
PR Newswire
02/12/2025

Frost & Sullivan: Health Recovery Solutions Receives the 2025 North American…

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. HRS excelled in both, demonstrating the ability to align strategic initiatives with provider needs while executing them with consistency, adaptability, and scale. Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. HRS excelled in both,...
PR Newswire
02/12/2025

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that it intends to develop its fully human anti-IL-6 receptor (IL-6R) monoclonal antibody, TZLS-501, and related assets (together “TZLS-501”) via a spinout into a separate publicly traded company, to enhance the strategic focus of each company and to drive value for shareholders. Tiziana shareholders at the record date will retain value from TZLS-501 through the...
Nasdaq GlobeNewswire
02/12/2025

Prefilled Syringes (PFS) Market Size to Grow USD 32.98 Billion by 2035 at a CAGR…

The landscape is transitioning from conventional vials to smart, polymer-based, safety-engineered, and auto-injector–compatible prefilled formats, enabling enhanced drug stability, reduced contamination risk, and superior usability across home-care and clinical settings. The landscape is transitioning from conventional vials to smart, polymer-based, safety-engineered, and auto-injector–compatible prefilled formats, enabling enhanced drug stability, reduced contamination risk, and superior...
PR Newswire
02/12/2025

Prescription Drugs Market Poised for Substantial Growth, Driven by Novel…

Download PDF Brochure: https://www.datamintelligence.com/download-sample/prescription-drugs-market Download PDF Brochure:https://www.datamintelligence.com/download-sample/prescription-drugs-market Browse in-depth TOC on "Prescription Drugs Market" 70 – Tables 66 – Figures 195 – Pages Market Dynamics: Catalysts and Strategic Imperatives for Growth The momentum of the global prescription drugs sector is significantly propelled by several intersecting growth drivers...
PR Newswire
02/12/2025

Pharmaceutical Grade Sodium Chloride Market worth $0.77 billion by 2030 -…

Pharmaceutical Grade Sodium Chloride Market Size & Forecast: Pharmaceutical Grade Sodium Chloride Market Size & Forecast: Pharmaceutical Grade Sodium Chloride Market Trends & Insights: Browse in-depth TOC on "Pharmaceutical Grade Sodium Chloride Market" 200 - Tables 50 - Figures 250 - Pages The pharmaceutical-grade sodium chloride market is expected to grow due to the rising demand for IV fluids, injectables, dialysis solutions, and oral rehydration therapies,...
PR Newswire
02/12/2025

bit.bio Publishes 2025 Sustainability Report

Male and female donor–derived cell lines and enhanced governance frameworks strengthen ethical and scientifically relevant research practices Male and female donor–derived cell lines and enhanced governance frameworks strengthen ethical and scientifically relevant research practices CAMBRIDGE, England , Dec. 2, 2025 /PRNewswire/ -- bit.bio , the global leader in cell programming technology, today announces the publication of its 2025 Corporate Sustainability Report ,...
PR Newswire
02/12/2025

Neusoft Medical Systems Unveils World's First 8cm Wide-Coverage Photon-Counting…

"We are honored to present advanced technologies that deliver superior imaging performance and intelligent care on this global stage," said Zhang Dan, Vice President of Neusoft Medical and General Manager of the International Business Center. "From the revolutionary NeuViz P10 photon-counting CT to our comprehensive AI-driven clinical platforms, each innovation is built on deep insights into user needs. We are committed to providing our global partners with tools that enhance…
PR Newswire
02/12/2025

2026 RANK PRIZES FOR NUTRITION AND OPTOELECTRONICS ANNOUNCED

Rank Prize in Nutrition Rank Prize in Nutrition ProfessorDavid E. Salt(University ofNottingham ) and ProfessorMartin Broadley(Rothamsted Research and University ofNottingham ) are the winners of the 2026 Rank Prize for Nutrition. Fusing advances in high-throughput elemental profiling with genetics, their ground-breaking research has revealed how plants accumulate mineral nutrients and trace elements from the soil. By profiling soil and crop quality, their work is transforming...
PR Newswire
02/12/2025

Ziwig Endotest®: Scientific Validation Published in NEJM Evidence

High-performance saliva-based diagnosis High-performance saliva-based diagnosis The Ziwig Endotest® was evaluated through the analysis of 109 salivary microRNAs, combining next-generation sequencing (NGS) with artificial intelligence. Diagnostic interpretations were performed blindly, without prior knowledge of the patients' clinical status, ensuring full methodological independence and robustness. The NEJM Evidence publication highlights exceptional diagnostic performance: These...
PR Newswire
02/12/2025

Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing…

Together, these results and the investment from the EIB, position Xeltis to advance confidently toward commercialization, bringing aXess – a revolutionary, first of its kind treatment – to market. Together, these results and the investment from the EIB, position Xeltis to advance confidently toward commercialization, bringing aXess – a revolutionary, first of its kind treatment – to market. Eliane Schutte, Chief Executive Officer, Xeltis, commented: "We are deeply grateful for the...
PR Newswire
02/12/2025

CARBIOS and Wankai New Materials sign the definitive agreement establishing a…

Clermont-Ferrand (France), 2 December 2025 (8:45 AM CET).In line with the commitment signed on November 6, 2025 1, CARBIOS (Euronext Growth Paris: ALCRB) and Wankai New Materials (« Wankai »), a listed subsidiary 2of Zhink Group, the 3 rdlargest PET producer in China and 4 thworldwide, announce the signing of the definitive agreement establishing a strategic partnership for the large-scale deployment of CARBIOS’s PET biorecycling technology in Asia, with the first step being the...
Nasdaq GlobeNewswire
02/12/2025

Proforma reporting of Essity's new business areas

Business areas as of January 1, 2026 Business areas as ofJanuary 1, 2026 Health & Medical Health & Medical encompasses the categories Incontinence Products Health Care and Medical Solutions. The offering includes incontinence products under the globally leading brand TENA and products in wound care, compression therapy and orthopedics under brands such as Leukoplast, Cutimed, JOBST, Actimove and Delta-Cast. Personal Care Personal Care encompasses the categories...
PR Newswire
02/12/2025

Enterome OncoMimics™ immunotherapy EO2401 shows survival benefit in Phase 2…

EO2401 in vivoimmune therapy + nivolumab +/- bevacizumab shows survival benefit in first recurrent glioblastomaData presented at 2025 SNO conference by lead investigatorParis, France – 2 DECEMBER 2025 (08:30 CET)Enterome, a clinical-stage company pioneering OncoMimics™ peptides, a new class of off-the-shelf, multi-targetedin vivoimmune therapies that induce a fast and potent expansion of memory T cells to fight cancer,today announces new survival analyses from Cohort 3...
Nasdaq GlobeNewswire
02/12/2025

Lundbeck to present comprehensive new bexicaserin dataset in patients with rare…

"Most DEEs are resistant to conventional anti-seizure medicines, leaving patients with very few options," said Johan Luthman, EVP and Head of Research & Development at Lundbeck. "The data for bexicaserin are compelling—indicating early seizure reductions that are sustained across diverse DEE syndromes. These results underscore its potential as a first-in-class treatment across this devastating range of epilepsies." "Most DEEs are resistant to conventional…
PR Newswire
02/12/2025

Tata Elxsi, University of Illinois Urbana-Champaign, and OSF HealthCare Partner…

Rural areas face steep barriers to healthcare access, including limited technology awareness, long distances to doctors, poor network connectivity, low population density, and inadequate payer coverage. A detailed OSF-based analysis by the Gies College of Business found that extending access to primary and preventive care in remote and rural areas significantly reduces avoidable emergency care visits among these populations. The initiative focuses on chronic and behavioral diseases and addresses…
PR Newswire
02/12/2025

Bavarian Nordic to Launch Share Buy-back Program of up to DKK 500 Million

COPENHAGEN, Denmark, December 2, 2025– Bavarian Nordic A/S (OMX: BAVA) today announced its intent to launch a one-time share buy-back program of up to DKK 500 million to be executed over the next 12 months.This decision should be viewed in the context of a current strong cash position, resulting from the recent sale of the Priority Review Voucher and a continued positive cash flow from operations. As of September 30, 2025, securities, cash and cash equivalents were DKK 2,978 million, of...
Nasdaq GlobeNewswire
02/12/2025

Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone…

Both medicines were approved by the European Medicines Agency (EMA) in September of this year following trials versus their reference product showing they are highly similar to the Prolia® (Amgen). Both medicines were approved by the European Medicines Agency (EMA) in September of this year following trials versus their reference product showing they are highly similar to the Prolia® (Amgen). Denosumab marks the company's second biosimilar launch within its bone health portfolio, further...
PR Newswire
02/12/2025

Tecan expands robotic workcell offering with acquisition of Wako Automation…

Männedorf, Switzerland, December 2, 2025 –The Tecan Group (SIX Swiss Exchange: TECN) today announced the acquisition of Wako Automation assets, including the flagship Director™ scheduling software and select hardware modules. The transaction was completed on December 1, 2025.It is Tecan’s strategic objective to expand its addressable market beyond liquid-handling-centric offerings and reinforce its leadership in laboratory automation. Advanced scheduling software enables customers to...
Nasdaq GlobeNewswire
02/12/2025
Altri  Comunicati